Business Information
The group's principal activities are to develop, manufacture and distribute generic drugs and active pharmaceutical ingredients. The group's products include antibiotics, narcotic analgesics, anti-infective and anti-tubercular drugs, antihistamines and antihistaminic decongestants, antitussives and steroids. The group's drug products are marketed in various forms, including liquid and powder preparations, compressed tablets and two-piece, hard-shelled capsules. The generic drug products are marketed by watson to drugstore chains and drug wholesalers. The group has manufacturing facilities in New York and Indiana.
|
|
Name |
Title
|
Email
|
| Peter Clemens | Sr. VP, CFO | Available | | Ron Spivey | Chief Scientific Officer, Sr. VP | N/A | | James Emigh | VP - Marketing, Administration | Available | | Andrew Reddick | Dir., CEO, Pres. | N/A | | Bruce Wesson | Dir. | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | N/A | (5,967) | | 2005 | N/A | (12,075) | | 2004 | 838 | (69,996)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
